Am J Transplant, Volume 21, Suppl 3 Archives - Page 101 of 139 - ATC Abstracts

2021 American Transplant Congress
Degree of T Cell Infiltration Predicts Treatment Response in Pediatric Liver Late Acute Cellular Rejection
M. Rogers, G. Begum, Q. Sun, A. Peters
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Late acute cellular rejection (ACR) occurs >6mo post-liver transplant and is associated with chronic rejection and allograft loss. Currently, no diagnostic features predict ACR…
2021 American Transplant Congress
A Comparison of Pediatric Intestine Transplant Between the Current Era (2015-2019) and the Peak Period (2002-2006)
S. Horslen¹, T. Weaver², M. Skeans²
¹Seattle Children's Hospital, Seattle, WA, ²SRTR, Minneapolis, MN
*Purpose: Demand for intestine transplants in children grew from its clinical inception in the late 1980s to a peak in 2007 of 111 small bowel-containing…
2021 American Transplant Congress
T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients
S. Kothari, T. Ku, D. Kumar, A. Humar, V. H. Ferreira
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…
2021 American Transplant Congress
Racial and Sexual Disparities in Solid Organ Transplant Outcomes Since Implementation of the Affordable Care Act Insurance Expansion Across Some States
H. Mohamed¹, C. Conceicao², A. Kumar¹, J. Buggs³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: Achieving solid organ transplantation traditionally requires access to health insurance. As such, women and people of color have faced barriers to obtaining solid-organ transplants.…
2021 American Transplant Congress
Evolving Trends in Risk Profiles and Outcomes in Older Adults Undergoing Kidney Re-Transplantation
S. Sandal¹, J. Ahn², M. Cantarovich¹, N. Chu², D. Segev², M. McAdams DeMarco²
¹McGill University, Montreal, QC, Canada, ²Johns Hopkins University, Baltimore, MD
*Purpose: The half-life of a kidney transplant (KT) is 8-12 years, and a significant proportion of patients end up with graft loss at age ≥65…
2021 American Transplant Congress
AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates
D. Berman¹, N. Kenyon¹, M. Willman¹, A. Gill², S. Perrin³, C. Ricordi¹
¹University of Miami, Miami, FL, ²ALS Therapy Development Institute, Cambridge, MA, ³Novus Therapeutics, Irvine, CA
*Purpose: Immune intervention with a CD40L specific monoclonal antibody (mAb, Hu5c8, Biogen) has previously been shown to safely and effectively prevent islet allograft (IA) rejection…
2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors
B. Aqel¹, H. Khamash², A. Moss³, D. E. Steidley⁴, R. C. Dickson¹
¹Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, ²Nephrology and Hypertension, Mayo Clinic, Phoenix, AZ, ³Transplant Surgery, Mayo Clinic, Phoenix, AZ, ⁴Cardiology, Mayo Clinic, Phoenix, AZ
*Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…
2021 American Transplant Congress
Survival After Heart Transplant vs. Simultaneous Heart Kidney Transplant by Degrees of Renal Dysfunction at Engraftment in the United States: A Multivariable Analysis
S. M. Riad¹, M. Aljuhani¹, S. Jackson², T. Alexy¹, H. Wadie³, C. Martin¹, R. Kandaswamy⁴
¹Medicine, University of Minnesota, Eden Prairie, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN, ³Transplant, Mayo Clinic, Jacksonville, FL, ⁴Surgery, University of Minnesota, Minneapolis, MN
*Purpose: There has been a rising trend for utilizing kidneys in heart transplant candidates with different renal dysfunction degrees without established criteria to address this…
2021 American Transplant Congress
High Interest, Low Payoff: Understanding Opportunities for Intervention for Those Exploring but Not Pursuing Paired Kidney Donation
A. D. Waterman¹, E. H. Wood¹, A. Thomas²
¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Johns Hopkins, Baltimore, MD
*Purpose: In 2016, the National Kidney Registry (NKR) established an online donor screening portal (DASH) to manage and track individuals interested in kidney paired donation…